Search Bar & Filters
Found 43 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a Master Protocol study focusing on the safety and tolerability of multiple amyloid-targeting drugs in both healthy adults and individuals diagnosed with Alzheimers disease AD. This study aims to evaluate if these drugs can remove amyloid plaque, clumps of protein in the brain linked to AD. Participants will enroll in one of two substudies, either A1D-MC-AT01 or the upcoming A1D-MC-AT02, to assess these treatments. The study involves administering the drug LY4405094 or a placebo either intravenously IV or subcutaneously SC to healthy volunteers and AD participants. Participants with AD will also undergo amyloid positron emission tomography PET scans using Florbetapir F18 or Florbetaben F18 injected intravenously to help monitor amyloid plaque in the brain. The study uses a randomized, double-blind design and includes several substudies depending on participant health status. Participants will be closely monitored throughout the study period, which lasts up to 160 days from baseline. Evaluations include medical exams, electrocardiograms ECGs, cognitive assessments such as the Mini-Mental State Exam MMSE, and brain imaging with PET scans and magnetic resonance imaging MRI. Study partners will assist participants with Alzheimers disease by providing support and consent. Researchers will track the number of participants assigned to each substudy and assess safety and tolerability during the trial.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating the effect on LDL cholesterol LDL-C and the safety and tolerability of a fixed-dose combination FDC of Laroprovstat and Rosuvastatin in patients who have not previously received lipid-lowering treatment LLT. Laroprovstat is a small molecule developed to reduce LDL-C in the blood, and this Phase III randomized study compares this combination with Laroprovstat alone, Rosuvastatin alone, and placebo in people with hypercholesterolaemia. Participants will be randomly assigned to one of several groups receiving daily oral doses of Laroprovstat, Rosuvastatin at two dose levels, the combination LaroprovstatRosuvastatin at two dose levels, or placebo matching these treatments. The study uses a factorial design and is double-blind, meaning neither participants nor researchers know which treatment is given. Treatment lasts for 8 weeks with assessments focused on changes in LDL-C levels. During the study, participants will attend visits for evaluations including blood tests to measure LDL-C and other cholesterol-related markers such as Apo B, non-HDL cholesterol, and total cholesterol. The main outcome measured is the relative change in LDL-C at 8 weeks. Safety and tolerability will also be monitored throughout. The entire participation period covers the treatment and assessment over the 8-week period.
Actively Recruiting
Researchers are studying the effects and safety of petrelintide compared with a placebo in adults who are overweight or have obesity, with at least one related health condition but without Type 2 Diabetes. This Phase III trial aims to assess how petrelintide, combined with a reduced-calorie diet and increased physical activity, supports weight management over time. Participants will receive either petrelintide or a matching placebo through weekly subcutaneous injections using a drug-device combination. The study lasts 64 weeks, during which all participants will follow a calorie-restricted diet and increase physical activity. The trial uses a randomized, double-blind design to compare the outcomes between the two groups. Throughout the study, participants will be regularly assessed for changes in body weight, waist circumference, blood markers like cholesterol and glucose, blood pressure, quality of life, and physical functioning. Safety will be monitored by tracking adverse events and immune responses. The main focus is the percentage change in body weight from the start to week 64. Participants involvement includes periodic visits for evaluations, questionnaires, and health measurements to monitor progress and safety.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of petrelintide compared to a placebo in adults who have overweight or obesity along with established cardiovascular disease. This Phase III study aims to understand how petrelintide, combined with a reduced-calorie diet and increased physical activity, may help manage weight in this population. Participants will receive either petrelintide or a matching placebo, both given as weekly subcutaneous injections using a drug-device combination product. The study follows a randomized, double-blind, placebo-controlled, parallel-group design, with treatment continuing up to 64 weeks. Both groups will also follow a reduced-calorie diet and increase physical activity during the trial. Throughout the study, participants will undergo regular assessments including measurements of body weight, waist circumference, blood tests for cholesterol and glucose levels, as well as questionnaires on quality of life and physical functioning. Researchers will monitor changes from baseline to week 64 and track any adverse events. The total participation duration spans the 64-week treatment period with ongoing monitoring of safety and effectiveness measures.
Actively Recruiting
Researchers are evaluating CTX310, a lipid nanoparticle formulation of CRISPR-Guide RNA-Cas9 nuclease, in adults aged 18 to 75 years with refractory dyslipidemias. This phase 1, open-label, multicenter trial aims to assess the safety and tolerability of CTX310 for in vivo editing of the ANGPTL3 gene in participants whose lipid disorders are resistant to available treatments. The study focuses on individuals with persistent dyslipidemias, including various types of hypercholesterolemia and hypertriglyceridemia. Participants will receive CTX310 as an intravenous infusion, with doses increasing over time to evaluate safety and tolerability. The trial is single-group and open-label, meaning all participants receive the investigational drug without a placebo group. The dosing and infusion schedules are designed to monitor how the treatment is processed and its effects on lipid levels. This study represents the first human trial of this CRISPR-based therapy. During the study, participants will be closely monitored through various assessments including safety evaluations, pharmacokinetics, pharmacodynamic responses, and measures of lipid levels over 12 months following the infusion. Researchers will track any adverse effects and the drugs impact on the participants dyslipidemia. Safety data will be collected from the time of infusion up to 12 months to fully understand CTX310s profile in this patient group.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
1-10 of 43
1